Investor Relations

Investor Relations

Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis in convenient administration forms.

With two unique projects, both developing towards important and potentially value-creating milestones, Cyxone is well positioned to deliver consequential benefits for patients, the health care system as well as for its shareholders. Cyxone’s goal is to out-license projects to strong partners after Phase 2 clinical trials to maximize their potential.

Cyxone’s financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) as adopted by the EU.

Download Cyxone’s Significant Accounting Principles as PDF

Investor Relations contact
Carl-Magnus Högerkorp, interim CEO
carl.hogerkorp@cyxone.com

Latest Press Release

  • Cyxone files regulatory submission to start clinical phase 2b study with Rabeximod

    June 23, 2022 12:23 (CEST)

    Cyxone (publ), a biotech company in autoimmune diseases, today filed a submission to the National Institute of Pharmacy and Nutrition (OGYEI) - the Hungarian Medical Product Agency - for approval to start a clinical phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). This first submission will be followed by applications to relevant regulatory authorities in other European countries.

    Read more

Financial Calendar

Half year Report 2022

Date: 24 August 2022

Interim Report Q3, 2022

Date: 27 October 2022

Year-end Report 2022

Date: 17 February 2023